Maxigen Biotech Stock

Maxigen Biotech OCF Margin

The Operating Cash Flow Margin of Maxigen Biotech (1783.TW) as of Aug 10, 2026 is 35.76 %. In the previous year, Operating Cash Flow Margin was 43.81 % — a change of -18.38% (lower).

OCF Margin

35.76 %

YoY

-18.38%

Last updated:

Operating Cash Flow Margin of Maxigen Biotech is 2026 35.76 % . Operating Cash Flow Margin of Maxigen Biotech was 2025 43.81 % . It decreases by -18.38% lower compared to the previous year.
Access this data via the Eulerpool API

Maxigen Biotech Stock analysis

What does Maxigen Biotech do? Maxigen Biotech Inc is a biotechnology company that was founded in 2000. The company, based in San Francisco, California, specializes in the development and production of biotechnological products and solutions. The company's goal is to lead in the biotechnology industry and have a positive impact on the health and well-being of people. To achieve its goals, the company has specialized in four business areas. The first business area is the research and development of new biotechnological products. The company has a team of scientists who work continuously on new innovative technologies and products. The company has already brought several products to market that have been very successful in the biotechnology industry. The second business area is the production of biotechnological products. The company has its own production facility equipped with state-of-the-art technologies. Here, the company's products are manufactured and delivered to customers worldwide. The third business area is the distribution of biotechnological products. The company has built a large distribution network to distribute its products in different parts of the world. The company works closely with pharmacies, laboratories, and hospitals to ensure that its products are made accessible to people. The fourth business area is the application of biotechnological products. The company works closely with doctors and healthcare facilities to ensure that its products are used in medical practice. The company is committed to using its products to improve the health and well-being of people worldwide. Maxigen Biotech Inc has introduced some remarkable products to the market in its history. One of the company's most important products is a highly effective antibiotic used to fight bacterial infections. The company has also developed a medication for the treatment of hypertension that is in high demand worldwide. Additionally, the company has developed a range of products for the treatment of cancer and other serious illnesses. The company has also made a significant contribution to public health. The company has developed technology to lower cholesterol levels in the blood, which can help prevent cardiovascular diseases. The company has also worked on the development of vaccines against infectious diseases that are still prevalent in some regions of the world. Maxigen Biotech Inc has received numerous awards and recognition in its history. The company is known for its innovation and high quality in the production of its products. The company is an example of how the biotechnology industry can contribute to improving the health and well-being of people worldwide. In summary, Maxigen Biotech Inc is a biotechnology company that specializes in the development and production of biotechnological products and solutions. The company has specialized in four business areas: research and development of new products, production of biotechnological products, distribution of biotechnological products, and application of biotechnological products. The company has introduced some remarkable products to the market in its history and has made a significant contribution to public health. The company has received numerous awards and recognition and is an example of excellence in the biotechnology industry. Maxigen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Maxigen Biotech stock

Operating Cash Flow Margin of Maxigen Biotech is 35.76 % in 2026.

Operating Cash Flow Margin of Maxigen Biotech changed from 43.81 % to 35.76 %, representing a -18.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Maxigen Biotech since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Maxigen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Maxigen Biotech

All Key Metrics — Maxigen Biotech